Background
PERSEUS was a phase III randomized open-label trial evaluating subcutaneous daratumumab plus bortezomib-lenalidomide-dexamethasone (D-VRd) versus VRd as induction, consolidation, and maintenance therapy flanking ASCT in transplant-eligible newly diagnosed multiple myeloma (NDMM). Building on the Phase II GRIFFIN trial evidence, PERSEUS provided the definitive Phase III confirmation of D-VRd superiority in this setting and incorporated an innovative MRD-driven maintenance strategy in which MRD-negative patients randomized to D-VRd could discontinue daratumumab during maintenance.
Interventions and follow up
Arm A (VRd): Bortezomib + lenalidomide + dexamethasone × 4 induction cycles → ASCT → VRd × 2 consolidation → lenalidomide maintenance until progression
Arm B (D-VRd): Subcutaneous daratumumab 1800 mg + VRd × 4 induction → ASCT → D-VRd × 2 consolidation → daratumumab + lenalidomide maintenance (with MRD-adapted daratumumab discontinuation) until progression
Primary endpoint: Progression-free survival (PFS)
mFollow-up: 47.5 months
Arm B (D-VRd): Subcutaneous daratumumab 1800 mg + VRd × 4 induction → ASCT → D-VRd × 2 consolidation → daratumumab + lenalidomide maintenance (with MRD-adapted daratumumab discontinuation) until progression
Primary endpoint: Progression-free survival (PFS)
mFollow-up: 47.5 months
Results
4-yr PFS: 84.3% vs 67.7% (HR 0.42, 95% CI 0.30–0.59, P<.001)
Sustained MRD negativity ≥12 mo: 46.8% vs 20.2% (P<.001)
CR or better: 87.9% vs 70.1%
sCR: 69.3% vs 45.5%
OS: data immature; HR 0.51 (95% CI 0.28–0.94, favoring D-VRd, not yet significant)
Sustained MRD negativity ≥12 mo: 46.8% vs 20.2% (P<.001)
CR or better: 87.9% vs 70.1%
sCR: 69.3% vs 45.5%
OS: data immature; HR 0.51 (95% CI 0.28–0.94, favoring D-VRd, not yet significant)
Adverse events
Overall: Grade ≥3 AEs 97.7% vs 94.0%; second primary malignancies 3.7% vs 2.3%
Hematologic: neutropenia 62.5% vs 51.3%
Infectious: infections Grade ≥3 26.0% vs 21.8%
Infusion-related/neurologic: infusion reactions 10.9% (Grade ≥3: 0.3%, low with SC formulation); peripheral neuropathy Grade ≥3 3.7% vs 3.4%
Hematologic: neutropenia 62.5% vs 51.3%
Infectious: infections Grade ≥3 26.0% vs 21.8%
Infusion-related/neurologic: infusion reactions 10.9% (Grade ≥3: 0.3%, low with SC formulation); peripheral neuropathy Grade ≥3 3.7% vs 3.4%
Conclusions
D-VRd significantly improved 4-year PFS (84% vs 68%, HR 0.42) and sustained MRD negativity rates more than doubling those of VRd in transplant-eligible NDMM, establishing D-VRd as the definitive standard-of-care quadruplet induction regimen in this setting and providing Phase III confirmation of the GRIFFIN Phase II results.
Key Limitations
Open-label design; OS data immature at primary analysis; MRD-adapted daratumumab discontinuation in maintenance is exploratory — not yet validated as a standard; the MRD threshold (10⁻⁵) may not be as sensitive as NGS-based 10⁻⁶ assessments; PERSEUS enrolled patients ≤70 years (median 59) — may not represent older transplant-eligible patients; no comparison to D-VTd (CASSIOPEIA backbone) or isatuximab-based quadruplets; cytogenetics subgroup (high-risk) showed benefit but smaller absolute gain.
Clinical Context
PERSEUS was published in NEJM 2024 and confirmed D-VRd as a preferred induction for transplant-eligible NDMM in the US, complementing the European CASSIOPEIA data for D-VTd. The 58% PFS hazard reduction (HR 0.42) is among the most dramatic seen in myeloma Phase III trials. The MRD-adapted maintenance concept in PERSEUS represents an early step toward biology-driven treatment de-escalation in myeloma. Together with CARTITUDE-4 (CAR-T in early relapse) and IMROZ (transplant-ineligible), PERSEUS defines the 2024 state-of-the-art for front-line myeloma management across transplant eligibility strata per ASCO/ESMO guidance.